Valsartan versus losartan
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Comparative Analysis of Valsartan and Losartan in Hypertension Treatment
Introduction to Angiotensin II Receptor Blockers (ARBs)
Angiotensin II receptor blockers (ARBs) are a class of medications commonly used to manage hypertension. Among these, valsartan and losartan are frequently prescribed. This article synthesizes research comparing the efficacy, safety, and additional health impacts of valsartan and losartan.
Efficacy in Blood Pressure Reduction
General Efficacy
Both valsartan and losartan have been shown to effectively reduce blood pressure in patients with mild to moderate essential hypertension. In a multicenter, randomized, double-blind trial, both drugs significantly reduced systolic and diastolic blood pressure (SBP and DBP) over a 12-week period, with no significant difference between the two in terms of efficacy. Another study confirmed that valsartan and losartan produced similar reductions in blood pressure, although valsartan had a slightly higher responder rate at the 8-week mark.
Combination Therapy
When combined with amlodipine, valsartan was found to be more effective than losartan in reducing blood pressure in patients inadequately controlled by amlodipine alone. The valsartan/amlodipine combination resulted in greater reductions in both systolic and diastolic blood pressure compared to the losartan/amlodipine combination.
Safety and Tolerability
Both valsartan and losartan are generally well-tolerated. Common adverse events such as headache, dizziness, and fatigue were reported at similar rates for both medications . However, valsartan was associated with a significantly lower incidence of dry cough compared to ACE inhibitors, making it a preferable option for patients who experience this side effect.
Impact on Serum Uric Acid Levels
One notable difference between the two drugs is their effect on serum uric acid levels. Losartan has been shown to significantly reduce serum uric acid levels, whereas valsartan does not have this effect. This difference could be clinically relevant for patients with conditions like gout, where managing uric acid levels is crucial .
Effects on Left Ventricular Hypertrophy
In patients with untreated essential hypertension and concentric left ventricular hypertrophy (LVH), both losartan and valsartan significantly reduced left ventricular mass index (LVMi). However, valsartan was more effective in this regard, also showing greater improvements in midwall systolic performance and left ventricular diastolic function.
Cost-Effectiveness
A cost-effectiveness analysis indicated that while losartan is expected to become more affordable as a generic drug, valsartan may still be more cost-effective in the long term due to its superior efficacy in lowering blood pressure and reducing cardiovascular events.
Conclusion
Both valsartan and losartan are effective and well-tolerated options for managing hypertension. Valsartan may offer slight advantages in terms of responder rates and efficacy in combination therapy, as well as in reducing left ventricular mass in patients with LVH. Losartan, on the other hand, has the added benefit of reducing serum uric acid levels, which can be particularly beneficial for patients with hyperuricemia or gout. The choice between these two ARBs should be tailored to the individual patient's health profile and specific needs.
Sources and full results
Most relevant research papers on this topic